Research and Markets: United States Epilepsy Market 2015-2019 with GlaxoSmithKline, Pfizer & UCB Dominating

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/lvtm26/epilepsy_market) has announced the addition of the "Epilepsy Market in the US 2015-2019" report to their offering.

The analysts forecast the Epilepsy market in the US to grow at a CAGR of 4.85% over the period 2014-2019

Epilepsy is a spectrum of brain disorders varying from benign to severe, disabling, and life-threatening symptoms. It is caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as in the majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures. Occurrence of two or more unprovoked seizures is an important criterion to diagnose a person as being epileptic.

One key trend emerging in this market is the reformulation of marketed drugs. Reformulated drugs have better tolerability and better dosing schedules than the original drugs. This increases the market acceptance of such drugs, driving the growth of the market.

According to the report, unmet medical needs are one of the key drivers of the market. Lack of safe, efficacious, and disease-modifying treatment is a major unmet need. Any drug that can cater to these demands is expected to drive the market during the forecast period.

Further, the report states that generic erosion is one of the major challenges hindering the growth of the Epilepsy market in the US as it decreases the revenue generated by individual drugs.

To calculate the market size, the report considers the revenue generated through the sales of anti-epileptic drugs approved in the US to treat the symptoms of epilepsy.

Key Vendors

  • GlaxoSmithKline
  • Pfizer
  • UCB

Key Topics Covered:

  1. Executive Summary
  2. List of Abbreviations
  3. Scope of the Report
  4. Market Research Methodology
  5. Disease Overview
  6. Introduction
  7. Market Landscape
  8. Market Segmentation by Generation of Drugs
  9. Buying Criteria
  10. Market Growth Drivers
  11. Drivers and their Impact
  12. Market Challenges
  13. Impact of Drivers and Challenges
  14. Market Trends
  15. Trends and their Impact
  16. Vendor Landscape
  17. Key Vendor Analysis

For more information visit http://www.researchandmarkets.com/research/lvtm26/epilepsy_market

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices